The making of bispecific antibodies
U Brinkmann, RE Kontermann - MAbs, 2017 - Taylor & Francis
During the past two decades we have seen a phenomenal evolution of bispecific antibodies
for therapeutic applications. The 'zoo'of bispecific antibodies is populated by many different …
for therapeutic applications. The 'zoo'of bispecific antibodies is populated by many different …
HER3 in cancer: from the bench to the bedside
L Gandullo-Sánchez, A Ocaña, A Pandiella - Journal of Experimental & …, 2022 - Springer
The HER3 protein, that belongs to the ErbB/HER receptor tyrosine kinase (RTK) family, is
expressed in several types of tumors. That fact, together with the role of HER3 in promoting …
expressed in several types of tumors. That fact, together with the role of HER3 in promoting …
[HTML][HTML] Understanding the biology of HER3 receptor as a therapeutic target in human cancer
HER3 belongs to the human epidermal growth factor receptor (HER) family which also
includes HER1/EGFR/erbB1, HER2/erbB2, and HER4/erbB4. As a unique member of the …
includes HER1/EGFR/erbB1, HER2/erbB2, and HER4/erbB4. As a unique member of the …
Targeting of erbB3 receptor to overcome resistance in cancer treatment
The erbB receptors, including the epidermal growth factor receptor (EGFR), erbB2 (also
known as HER2/neu), erbB3 (or HER3), and erbB4 (or HER4), are often aberrantly activated …
known as HER2/neu), erbB3 (or HER3), and erbB4 (or HER4), are often aberrantly activated …
Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
Patients with gastric and esophageal (GE) adenocarcinoma tumors in which the oncogene
ERBB2 has been amplified are routinely treated with a combination of cytotoxic …
ERBB2 has been amplified are routinely treated with a combination of cytotoxic …
Molecular mechanisms of trastuzumab‐based treatment in HER2‐overexpressing breast cancer
R Nahta - International Scholarly Research Notices, 2012 - Wiley Online Library
The past decade of research into HER2‐overexpressing breast cancer has provided
significant insight into the mechanisms by which HER2 signaling drives tumor progression …
significant insight into the mechanisms by which HER2 signaling drives tumor progression …
Development of effective therapeutics targeting HER3 for cancer treatment
HER3 is the third member of the human epidermal growth factor receptor (HER/EGFR)
family, and unlike its other family members, is unique due to its minimal intrinsic kinase …
family, and unlike its other family members, is unique due to its minimal intrinsic kinase …
Targeting HER3 using mono-and bispecific antibodies or alternative scaffolds
The human epidermal growth factor receptor 3 (HER3) has in recent years been recognized
as a key node in the complex signaling network of many different cancers. It is implicated in …
as a key node in the complex signaling network of many different cancers. It is implicated in …
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
Background Elevated expression of erbB3 receptor has been reported to induce resistance
to therapeutic agents, including trastuzumab in erbB2-overexpressing breast cancer. Our …
to therapeutic agents, including trastuzumab in erbB2-overexpressing breast cancer. Our …
Alteration of WWOX in human cancer, a clinical view
I Baryła, E Styczeń-Binkowska… - … Biology and Medicine, 2015 - journals.sagepub.com
WWOX gene is located in FRA16D, the highly affected chromosomal fragile site. Its tumor
suppressor activity has been proposed on a basis of numerous genomic alterations reported …
suppressor activity has been proposed on a basis of numerous genomic alterations reported …